

5. Visentin A, Pravato S, Castellani F, et al. From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance. *Cancers (Basel)*. 2022;14(6):1562. doi: 10.3390/cancers14061562.
6. Sandecká V, Pour L, Adam Z, et al. Monoklonální gamapatie nejasného významu (MGUS). *Klin onkol*. 2018;31(4):270-276.
7. Sandecká V, Hájek R, Adam Z, et al. Monoklonální gamapatie nejasného významu s nízkým a vysokým stupněm rizika: výstupy z analýz RMG registru České myelomové skupiny pro praxi. *Klinická biochemie a metabolismus*. 2015;23(2):53-59.
8. Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. *Amer J Med*. 1978;64:814-826.
9. Kyle RA, Larson DE, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. *N Engl J Med*. 2018;378(3):241-249.
10. Landgren O, Kyle RA, Pfeiffer R, et al. Monoclonal gammopathy of undetermined significance consistently precedes multiple myeloma: a prospective study. *Blood*. 2009;113:5412-5417.
11. Weiss BM, Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients. *Blood*. 2009;113:5418-5422.
12. Axelsson U, Bachmann R, Hällén J. Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. *Acta Medica Scandinavica*. 1966;179:235-247.
13. Saleun JP, Vicariot M, Deroff P, et al. Monoclonal gammopathies in the adult population of Finistère, France. *J Clin Pathol*. 1982;35:63-68.
14. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. *N Engl J Med*. 2006;354:1362-1369.
15. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. *N Engl J Med*. 2002;346:564-569.
16. Dispenzieri A, Katzman JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population based cohort study. *Lancet*. 2010;375(9727):1721-1728.
17. Girard LP, Soekkojo CY, Ooi M, et al. Immunoglobulin M Paraproteinaemias. *Cancers (Basel)*. 2020;12(6):1688. doi: 10.3390/cancers12061688.
18. Mian M, Franz I, Wasle I, et al. „Idiopathic Bence-Jones proteinuria”: a new characterization of an old entity. *Ann Hematol*. 2013;92(9):1263-1270.
19. Vachon CM, Kyle RA, Therneau TM, et al. Increased risk of monoclonal gammopathy in first degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. *Blood*. 2009;114:785-790.
20. Langren P, Kristinsson SY, Goldin LR, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. *Brit J Haematol*. 2009;114(4):791-795.
21. Greenberg AJ, Rajkumar SV, Larson DR, et al. Increased prevalence of light chain monoclonal gammopathy of undetermined significance in first degree relatives of individuals with multiple myeloma. *Brit J Haematol*. 2012;157(4):472-475.
22. Landgren O, Kyle RA, Hoppin JA, et al. Pesticide exposure and risk of monoclonal gammopathy on undetermined significance in the Agricultural Health Study. *Blood*. 2009;113:6386-6391.
23. McShane CM, Murray LJ, Landgren O, et al. Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. *Cancer Epidemiol Biomarkers Prev*. 2014;23(2):332-342.
24. Kyle RA, Durie BG, Rajkumar SV, et al. International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia*. 2010;24(6):1121-1127.
25. Kyle RA, Therneau TM, Dispenzieri A, et al. Immunoglobulin M monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia. *Clin Lymphoma Myeloma Leuk*. 2013;13(2):184-186.
26. Ludwig H, Boccardo M, Moreau P, et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. *Leukemia*. 2021;35(1):31-44. doi: 10.1038/s41375-020-01016-0.
27. Lin P, Hao S, Handy BC, et al. Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. *Amer J Clin Pathol*. 2005;123:200-205.
28. Adam Z, Štěpánková S, Sirotková A, et al. Selhání ledvin u pacientky s chronickou B-lymfocytární leukémií (B-C-LL) vzniklé na podkladě tvorby odlišných válců v tubulech ledvin z monoklonálních lehkých řetězců (casth nephropathy). Přínos stanovení volných lehkých řetězců imunoglobulinů pro časnou diagnostiku této komplikace. *Vnitř. Lék*. 2011;57(2):214-221.
29. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. *Brit J Haematol*. 2006;134:573-589.
30. Raposo A, Peixoto D, Bogas M. Monoclonal gammopathy and rheumatic diseases. *Acta Reumatol Port*. 2014;39(1):12-18.
31. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. *Blood*. 2005;106:812-817.
32. Kyle RA, Therneau TM, Rajkumar SV, et al. Long term follow up of 241 patients with monoclonal gammopathy of undetermined significance. The original Mayo Clinic series 25 years later. *Mayo Clin Proc*. 2004;79:859-866.
33. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. *J Clin Oncol*. 2002;20:1625-1634.
34. Gregersen H, Mellemkjær L, Ibsen JS, et al. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. *Haematologica*. 2001;86:1172-1179.
35. Kumar S, Rajkumar SV, Kyle RA, et al. Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. *J Clin Oncol*. 2005;23:5668-5674.
36. Ščudla V, Minařík J, Pika T, et al. Diferenciální diagnostika monoklonálních gamapatií z pohledu klinické praxe. II. Monoklonální gamapatie nejistého významu a ostatní monoklonální gamapatie nezhoubného původu. *Interní med*. 2018;20(1):44-48.
37. Rosinol L, Cibera MG, Montoto S, et al. Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein. *Mayo Clin Proc*. 2007;82:428-434.
38. Dizdar O, Erman M, Cankurtaran M, et al. Lower bone mineral density in geriatric patients with monoclonal gammopathy of undetermined significance. *Ann Hematol*. 2008;87:57-60.
39. Pepe J, Petrucci MT, Nofroni I, et al. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of uncertain significance. *Brit J Haematol*. 2006;134:485-490.
40. Melton LJ, Rajkumar SV, Khosla S, et al. Fracture risk in monoclonal gammopathy of undetermined significance. *J Bone Miner Res*. 2004;19:25-30.
41. Kristinsson SY, Tang M, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. *Blood*. 2010;116(15):2651-2655.
42. Gregersen H, Norgaard M, Severinsen MT, et al. Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism. *Eur J Haematol*. 2011;86(2):129-134.
43. Kristinsson SY, Tang M, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of infections. A population based study. *Haematologica*. 2012;97(6):854-858.
44. Aslam N, Trautman CL, Sher T. Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance. *Transplant Direct*. 2021;7(8):e723. doi: 10.1097/TXD.0000000000001176.
45. Adam Z, Bolcak K, Stanicek J, et al. Fluorodeoxyglucose positron emission tomography in multiple myeloma, solitary plasmacytoma and monoclonal gammopathy of unknown significance. *Neoplasma*. 2007;54(6):536-640.
46. Sandecká V, Adam Z, Krejčí M, et al. Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience et al. *Neoplasma*. 2020;67(4):939-945.
47. Spáčilová J, Šolcová L, Tichý M. Transientní monoklonální gamapatie – kazuistika. *Klinická biochemie a metabolismus*. 2012;20(2):88-90.
48. Sandecká V, Hájek R, Pour L, et al. A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. *European journal of haematology*. 2017;99(1):80-90.
49. van de Donk NW, Palumbo A, Johnsen HE, et al. European Myeloma Network. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. *Haematologica*. 2014;99(6):984-996. doi: 10.3324/haematol.2013.100552.
50. Landgren O. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events. *Hematology Am Soc Hematol Educ Program*. 2021;2021(1):662-672. doi: 10.1182/hematology.2021000303.
51. Schoot TS, van Apeldoorn M, Sinnige HAM, et al. Monoclonal gammopathy. with significance: case series and literature review. *Neth J Med*. 2020;78(4):191-195.
52. Merlini G, Stone J. Dangerous small B-cell clones. *Blood*. 2006;108(8):2520-2530.
53. Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. *Blood*. 2018;131(2):163-173. doi:10.1182/blood-2017-09-807560.
54. Adam Z. Poškození organismu monoklonálními imunoglobuliny a možnosti léčby. Část první. *Vnitř. Lék*. 1993;39(8):817-827.
55. Adam Z. Poškození organismu monoklonálními imunoglobuliny a možnosti léčby. Část druhá. *Vnitř. Lék*. 1993;39(10):1013-1021.
56. Leung N, Bridoux F, Hutchison CA, et al. International Kidney and Monoclonal Gammopathy Research Group. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. *Blood*. 2012;120(2):4292-4295.
57. Bridoux F, Leung N, Hutchison CA, et al. International Kidney and Monoclonal Gammopathy Research Group. Diagnosis of monoclonal gammopathy of renal significance. *Kidney Int*. 2015;87(4):698-711.
58. Merlini G. AL amyloidosis: from molecular mechanisms to targeted therapies. *Hematology Am Soc Hematol Educ Program*. 2017;(2017):1-12.
59. Flodrová P, Pika T, Flodr P. AL amyloidóza v obrazech. *Transfúze a hematologie dnes*. 2014;20(3):76-80.
60. Pika T, Hájek R, et al. Diagnostika a léčba systémové AL-amyloidózy. Doporučení České myelomové skupiny. *Transfúze 2022*;28(Supplementum 1):5-40.
61. Vignon N, Javaugue V, Alexander MP, et al. Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients. *Leukemia*. 2017;31(1):123-129.
62. Horáčková M, Kamínková J, Polačková M, et al. Méně obvyklá příčina chronické tubulointersticiální nefritidy komplikované získaným Fanconiho syndromem. *Vnitř. Lék*. 1989;35(2):179-183.
63. Kanagal-Shamanna, Xu-Monette ZY, Miranda RN, et al. Crystal-storing histiocytosis: a clinicopathological study of 13 cases. *Histopathology*. 2016;68(4):482-491.
64. Wiese-Hansen H, Leh F, Lodvrig Hemsing A, et al. Immu-